CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients

European Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2009, Pages 473-481

  Satoh, Shigeru ^a   Saito, Mitsuru ^a   Inoue, Takamitsu ^a   Kagaya, Hideaki ^b   Miura, Masatomo ^b   Inoue, Kazuyuki ^b   Komatsuda, Atsushi ^a   Tsuchiya, Norihiko ^a   Suzuki, Toshio ^b   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chronic allograft nephropathy; CYP3A5 A6986G polymorphism; CYP3A5 expresser; Pharmacogenetics; Subclinical acute rejection; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLELE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PHARMACOGENETICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE DRUG DOSE; ALLOTRANSPLANTATION; ASIAN; GENETICS; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP3A; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 67349144040     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0606-3     Document Type: Article

References (26)

1. R Venkataramanan A Swaminathan T Prasad A Jain S Zuckerman V Warty J tmp McMichael J Lever G Burckart T Starzl 1995 Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 404 430
2. V Haufroid P Wallenmacq V VanKerckhove L Elens M De Meyer DC Eddour J Malaise D Lison M Mourad 2006 CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 6 2706 2713
3. DA Hessenlink RH van Schaik IP van der Heiden M van der Werf PJ Gregoor J Lindemans W Weimar T van Gelder 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245 254
4. V Haufroid M Mourad V Van Kerckhove J Wawrzyniak M De Meyer DC Eddour J Malaise D Lison JP Squifflet P Wallemacq 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant recipients Pharmacogenetics 14 147 154
5. N Tsuchiya S Satoh H Tada Z Li C Ohyama K Sato T Suzuki T Habuchi T Kato 2004 Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 1182 1187
6. H Tada N Tsuchiya S Satoh H Kagaya Z Li K Sato M Miura T Suzuki T Kato T Habuchi 2005 Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 1730 1732
7. JN Roy A Barama C Poirier B Vinet M Roger 2006 Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients Pharmacogenet Genomics 16 659 665
8. IA tmp MacPhee S Fredericks T Tai P Syrris ND Carter A Johnston L Goldberg DW Holt 2004 The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 914 919
9. DR Kuypers H de Jonge M Naesens E Lerut K Verbeke Y Vanrenterghem 2007 CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 711 725
10. NA Undre J van Hooff M Christiaans Y Vanrenterghem J Donck U Heeman M Kohnle B Zanker W Land JM Morales A Andres A Schafer P Stevenson 1999 Low systemic exposure to tacrolimus correlates with acute rejection Transplant Proc 31 296 298
11. C Staatz P Taylor S Tett 2001 Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation Nephrol Dial Transplant 16 1905 1909
12. H Tada S Satoh M Iinuma N Shimoda M Murakami Y Hayase T Kato T Suzuki 2003 Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection J Clin Pharmacol 43 859 865
13. K Inoue M Miura S Satoh H Kagara M Saito T Habuchi T Suzuki 2007 Influence of UGT1A7 and UGT1A9 intronic I1399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients Ther Drug Monit 29 299 304
14. LC Racusen K Solez RB Colvin SM Bonsib MC Castro T Cavallo 1999 The Banff 97 working classification of renal allograft pathology Kidney Int 55 713 723
15. K Solez RB Colvin LC Racusen B Sis PF Halloran PE Birk 2007 Banff '05 meeting report; differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN) Am J Transplant 7 518 526
16. K Numakura S Satoh N Tsuchiya Y Horikawa T Inoue H Kakinuma S Matsuura M Saito H Tada T Suzuki T Habuchi 2005 Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus Transplantation 80 1419 1424
17. F Vincenti DA Laskow JF Neylan R Mendez AJ Matas 1996 One-year follow up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group Transplantation 61 1576 1581
18. Japanese FK506 Study Group 1992 Japanese study of kidney transplantation. 1. Results of early phase II study Transplant Int 5 Suppl 1 S524 S528
19. CM Spencer KL Goa JC Gillis 1997 Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation Drugs 54 925 975
20. SA Gruber JM Hewitt AL Sorenson DL Barber L Bowers G Rynders L Arrazola AJ Matas ME Rosenberg DM Canafax 1994 Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation J Clin Pharmacol 34 859 864
21. AB Jain K Abu-Elmagd H Abdallah V Warty J Fung S Todo TE Starzl R Venkataramanan 1993 Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion J Clin Pharmacol 33 606 611
22. S Satoh H Tada Y Tachiki N Tcuchiya N Shimoda T Akao K Sato T Habuchi T Suzuki T Kato 2001 Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration Int J Urol 8 353 358
23. J Miller R Mendez JD Pirsch SC Jensik 2000 Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF dose-ranging kidney transplant study group Transplantation 69 875 880
24. F Ortiz T Paavonen T Tornroth P Koskinen P Finne K Salmela L Kyllonen C Gronhagen-Riska E Honkanen 2005 Predictors of renal allograft histologic damage progression J Am Soc Nephrol 16 817 824
25. RC Bakker AA Hollander MJ Mallat JA Bruijin LC Paul JW de Fijter 2003 Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy Kidney Int 64 1027 1034
26. JK Lamba YS Lin EG Schuetz KE Thummel 2002 Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Delivery Rev 54 1271 1294